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CHAPTER I 
INTRODUCTION 
1.1 Autoimmune Thyroiditis 
1.1.1 Hashimoto's thyroiditis (HT) 
Hashimoto's thyroiditis (HT) is one of the common autoimmune thyroid diseases (AITD) 
in humans. HT, also named autoimmune or chronic lymphocytic thyroiditis, was first 
described by the Japanese surgeon, Hakaru Hashimoto in 1912 (Hashimoto 1912). This 
disease occurs as a result ofthe failure of immunologic self-tolerance. Autoreactive T-
cells, both CD4+ T -cells and CD8+ T -cells, escaping from intrathymic deletion and 
anergy, are activated in local lymph nodes under certain conditions, then accumulate and 
attack the thyroid gland where organ-specific self antigens, such as thyroglobulin (Tg) 
and thyroid peroxidase (TPO) are expressed (Ai et al. 2003, Weetman and McGregor 
1994). Anti-thyroglobulin antibody (Tg-Ab) (Campbell et al. 1956) and anti-thyroid 
peroxidase antibody (TPO-Ab) (Kotani et al. 1986) also arise in patients with HT. These 
two autoantibodies work as indicators for HT diagnosis and predictors of future 
autoimmune hypothyroidism (Weetman 2004). However, the presence ofTg-Ab and 
TPO-Ab alone does not indicate the occurrence ofHT because Tg-Abs and TPO-Abs are 
also detected in healthy people, with variable prevalence according to gender and age 
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(Weetman 2004). Also, about 20% of patients with thyroid carcinoma are Tg-Ab positive 
(Weetman 2004). Due to above immune responses, the thyroid gland is destroyed 
gradually and shows pathological features such as: goiter, mononuclear cell infiltration, 
fibrosis, and thyroid cell hyperplasia. With the destruction of the thyroid gland, the 
secretion of thyroidal hormones, triidothyronine (T3) and thyroxine (T4) is reduced; 
hypothyroidism and clinical symptoms such as a diffuse goiter, fatigue, depression, 
sensitivity to cold, weight gain, muscle weakness, coarsening of the skin, dry or brittle 
hair, constipation, increased menstrual flow appear in patients. The natural course ofHT 
shows a chronic progression with a long subclinical phase in which the patients with HT 
have no distinct clinical symptoms (Ai et al. 2003). 
Besides the immunological factors, genetic and environmental influences all contribute to 
the initiation and development ofHT. The human leukocyte antigen (HLA) region was 
thought to contain one of the most important HT susceptibility genes because many 
immune response genes are harbored in this polymorphic region. Epidemiological studies 
in Caucasians showed that HLA-DR3 is associated with HT (Tandon et al. 1991). The 
association of goitrous HT with HLA-DR5 has been reported in other studies, with a 
relative risk (R.R.) of3.1 (Farid et al. 1981). Other immune related genes have also been 
considered as susceptibility genes, such as the cytotoxic T lymphocyte antigen-4 (CTLA-
4) (Ban and Tomer 2003). However, CTLA-4 does not confer specific susceptibility to 
HT (Ban and Tomer 2003). In fact, it is associated and linked with many autoimmune 
diseases including AITD (Nithiyananthan et al. 2002, Kotsa et al. 1997). The role of 
2 
iodine, as the most important environmental factor in HT induction, has been confirmed 
in clinical (Bournaud and Orgiazzi 2003) and animal models (Ruwhof and Drexhage 
2001). Both sudden changes in iodine intake (Boukis et al. 1983) and prolonged exposure 
to a high but constant iodine intake (Harach et al. 1985) facilitate the incidence of 
thyroiditis and the development of thyroid autoantibodies. 
1.1.2 Experimental autoimmune thyroiditis (EAT) as an animal model ofHT 
Experimental autoimmune thyroiditis (EAT), an animal model ofHT, provides unique 
insights into the etiology and pathogenesis of autoimmune thyroiditis. Studies related to 
the two types of EAT, induced and spontaneous, will be discussed in the next two 
sections. 
1.1.2.1 Induced EAT 
1.1.2.1.1 Induced EAT animal models 
The first EAT model was described by Witebsky and Rose in 1956. They reported that 
rabbits immunized with homologous thyroid tissue emulsified in complete Freund's 
adjuvant (CF A) produced thyroid autoantibodies and showed lymphocytic infiltration in 
the thyroid gland (Rose and Witebsky 1956). Since then, by using similar methods, EAT 
has been successfully induced in various animal species: guinea pigs, dogs (Terplan et al. 
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1960), rats (Jones and Roitt 1961), monkeys (Rose et al. 1966) and mice (Rose et al. 
1971). Although both heterologous and homologous Tg are used in EAT induction, 
homologous Tg usually elicits more severe EAT than heterologous Tg. This may be due 
to thyroiditogenic epitopes unique to selfTg, in addition to sharing conserved 
thyroiditogenic epitopes . Other protocols have also been proven to be efficient in 
inducing EAT. In 1977, Esquivel and his colleagues found that the use of 
lipopolysaccharide (LPS) as an adjuvant was equivalent to CFA at the same mouse Tg 
(mTg) dose (Esquivel et al. 1977). Later, mTg conjugated to a monoclonal antibody 
(MAb) specific for MHC-II molecule (anti-I-Ak), instead of an adjuvant, was found to 
successfully induce EAT in CBA mice (Balasa and Carayanniotis 1993). Moreover, EAT 
can be induced by repeated high doses of syngeneic mTg in the absence of adjuvant 
(ElRehewy et al. 1981 ). 
1.1.2.1.2 Association ofEAT susceptibility with MHC gene expression 
During the establishment of the mouse EAT model, it was shown that some mice respond 
well to mTg immunization, while others respond poorly or not at all under the same 
conditions. These observations led to the discovery that susceptibility of mouse strains to 
EAT is linked to H-2 genes (Vladutiu and Rose 1971). Mice with H-2 haplotypes k and s 
are susceptible, while mice with H-2h, H-2d, H-2f-haplotypes are resistant and mice with 
H-2q are intermediate (Vladutiu and Rose 1971). In addition, the evidence for human 
leukocyte antigen (HLA) association with HT was explored by using HLA transgenic 
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mouse models (Kong et al. 2003, Kong et al. 1996). It was found that EAT-resistant 
BlO.M mice became susceptible after introduction of the HLA-DR3 transgene (Kong et 
al. 1996). In contrast, HLA-DR2 and HLA-DR4 transgenic mice did not develop EAT 
after challenge with mTg or human Tg (hTg) (Kong et al. 2003). 
1.1.2.1.3 EAT as T -cell mediated disease 
The central role ofT -cells in the induction of EAT has also been demonstrated in animal 
models. By adoptive transfer ofmTg-primed and activated spleen cells to normal 
syngeneic recipients, Braley-Mullen eta/. observed that similar incidence and severity of 
EAT was induced in these syngeneic recipients and in mice directly immunized with 
mTg (Braley-Mullen et al. 1985). They confirmed that EAT was transferred by T-cells 
since removal ofB-cells from the culture did not abolish the ability of cells to transfer 
EAT. Subsequent studies illustrated that both CD4+ and CD8+ T-cells were required to 
initiate thyroiditis (Flynn et al. 1989, Conaway et al. 1989, Conaway et al. 1990). CD4+ 
T -cells were the primary population responsible for the initial transfer and development 
ofEAT (Flynn et al. 1989). Kinetic analysis ofT-cell subsets infiltrating the thyroid 
clearly showed CD4+ T -cells accumulating with higher percentages than CD8+ T -cells in 
the early phase of transferred EAT with a relative increase of CD8+ T -cells later. These 
CD8+ T-cells were probably involved in EAT pathogenesis by cytotoxic effects 
(Conaway et al. 1989, Conaway et al. 1990). 
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1.1.2.2 Spontaneous autoimmune thyroiditis (SAT) 
Spontaneous autoimmune thyroiditis (SAT), a type of disease similar to HT, also occurs 
in animals (Weetman and McGregor 1994 ). Several animal models of SAT have been 
described (Wicket al. 1989, Stemthal et al. 1981, Many et al. 1995, Braley-Mullen et al. 
1999). One of the well established models is the obese strain (OS) chicken, which is 
characterized as hypothyroidism after autoimmune thyroidal destruction (Wick et al. 
1989). The biobreeding diabetes-prone (BB-DP) rat, a model for insulin-dependent 
diabetes mellitus (IDDM), has also shown high incidence of SAT (Stemthal et al. 1981 ). 
Usually, there is no significant hypothyroidism following the development of 
lymphocytic thyroiditis in BB-DP rats (Stemthal et al. 1981). Another animal model of 
autoimmune diabetes, the nonobese diabetes (NOD) mouse, also suffers from 
autoimmune thyroiditis (Many et al. 1995). Interestingly, the NOD MHC-congenic strain, 
NOD.H-2h4 develops only SAT, not diabetes (Braley-Mullen et al. 1999). Studies of SAT 
models indicate that a combination of genetic, immunological and environmental factors 
results in the susceptibility to autoimmune thyroiditis. 
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1.2 Mapping T cell epitopes in EAT 
1.2.1 Thyroglobulin (Tg) as an autoantigen in EAT 
The important role ofTg as an autoantigen in autoimmune thyroiditis was elucidated 
based on two major findings: in 1956, Campbell et al. (Campbell et al. 1956) reported 
that Tg-specific Abs were detected in sera of patients with HT; in the same year, by the 
efforts ofRose and Witebsky (Rose and Witebsky 1956), EAT was successfully induced 
in rabbits by immunization with homologous thyroid extract in adjuvant. These animals 
showed similar pathological features as HT in humans and developed autoantibodies 
recognizing Tg. Since then, numerous studies have confirmed the immunopathogenicity 
ofTg in EAT and pointed out the pivotal role ofTg-specific T-cells in the induction and 
effector phase ofEAT (Weetman and McGregor 1994). 
Tg represents up to 75% ofthe total protein in the thyroid gland (Malthiery et al. 1989). 
This large, highly conserved glycoprotein consists of two monomeric polypeptide chains 
making up a molecular weight of approximate 660 kDa. The two constituent chains are 
thought to be identical when synthesized, but heterogeneous after post-translational 
modifications such as glycosylation and iodination (Dunn and Dunn 2000). Tg is 
synthesized in the endoplasmic reticulum (ER) ofthyrocytes, then transported to the 
Golgi body for sulfation and glycosylation, and eventually secreted to the apical cell 
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surface where iodination occurs (Van Herle et al. 1979, Ekholm 1990). Metabolically, Tg 
is working as a prothyroid hormone. It provides the matrix which incorporates and stores 
iodine in iodotyrosine residues to form the thyroid hormones: triiodothyronine (T3) and 
thyroxine (T4) (Taurog 2000). 
Tg is also highly conserved among different species (Vali et al. 2000). So far, the 
complete primary sequences ofhuman (h) (Malthiery and Lissitzky 1987), bovine (b) 
(Mercken et al. 1985) and mouse (m) (Caturegli et al. 1997) have been deduced from 
their mRNA and comprise 2767, 2769 and 2768 amino acid residues respectively. High 
identity in the amino acid sequence is revealed among these species: hTg and bTg 
(77.3%), bTg and mTg (73.5%), and mTg and hTg (71.8%) (Vali et al. 2000). Moreover, 
Tg shows significant internal homology (Vali et al. 2000). TheN-terminal end of this 
molecule has three types of repetitive cysteine-rich domains. The type I domain contains 
10 repeats of about 60 amino acid residues between position 1-1200. The type II domain 
has 3 repeats of 14-17 residues between position1436-1483 and there are 5 repeats 
between position1583-2170 in the type III domain (Vali et al. 2000). The functional role 
of these repetitive structures has been hypothesized by Molina eta!. (Molina et al. 1996). 
The type I repeats may function as binders and reversible inhibitors of the proteases that 
are involved in proteolytic processing ofTg. In contrast, the C-terminal end lacks internal 
homology, but this cysteine-poor region is homologous to acetylcholinesterase (Ach) and 
other carboxylesterases (Takagi et al. 1991). 
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There are two biosynthetic features, which influence the immunological effects of Tg 
(Carayanniotis 2003). First, Tg is not a sequestered antigen since it is continuously 
released into the circulation by transcytosis (Herzog 1983). It is not clear whether Tg is 
released in the circulation in an intact form or as smaller immunoreactive fragments. 
Processing of smaller Tg fragments by antigen-presenting cells (APC) in vivo to generate 
thyroiditogenic epitopes may be different from the processing of intact Tg in vitro 
(Carayanniotis and Rao 1997). Second, iodination ofTg may influence the 
immunopathogenicity of this molecule (Carayanniotis 2003). Poorly iodinated Tg 
dissociates easily, while increasing iodination stabilizes this dimer (Dunn and Dunn 
2000). Mice develop more severe EAT when immunized with highly iodinated Tg (Dai et 
al. 2002), suggesting that iodination ofTg enhances its pathogenicity. Epidemiological 
data have also shown an increasing prevalence of thyroiditis which parallels dietary 
supplementation with iodine (Bournaud and Orgiazzi 2003). 
1.2.2 T -cell epitope mapping in Tg 
The findings that T -cells play a critical role in eliciting thyroiditis encouraged the 
identification of pathogenic T -cell epitopes within T g. Given the huge molecular size of 
Tg, the traditional method of epitope mapping, such as the use of overlapping peptides to 
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screen and test pathogenic determinants in autoantigen, is not suitable for Tg. Despite the 
technical challenges, efforts from different research groups have so far mapped 23 
thyroiditogenic Tg peptides by diverse approaches (Carayanniotis 2003, Flynn et al. 2004, 
Li and Carayanniotis 2006). Fifteen known EAT -causing peptides have been identified in 
mTg, six in hTg and two have been localized around hormonogenic sites identical 
between hTg and mTg (Carayanniotis 2003, Flynn et al. 2004, Li and Carayanniotis 
2006). 
mTg-derived pathogenic peptides 
Most ofmTg-derived pathogenic peptides have been uncovered by the use of 
computerized algorithms that scan the primary a.a. sequence for potential MHC-binding 
peptides (Chronopoulou and Carayanniotis 1992, Carayanniotis et al. 1994, Rao et al. 
1994, Rao and Carayanniotis 1997, Verginis et al. 2002, Li and Carayanniotis 2006). This 
method is based on the observation that the susceptibility of EAT is linked to H-2 genes. 
H-2k and H-25 strains are good responders, while H-2b,d strains are low responders 
(Vladutiu and Rose 1971 ). Thus, pathogenic determinants were found presented in the 
context ofEk, Ak or A8 molecules and different MHC class II haplotypes were found to 
influence the pathogenicity ofTg peptides. For example, the 13 mer peptide (2596-2608) 
elicits EAT in H-2\ but not H-28 mice (Verginis and Carayanniotis 2004) and vice versa, 
the peptide (2694-2711) induces thyroiditis in H-25 but not H-2k mice (Carayanniotis et al. 
1994 ), indicating that EAT may be induced via recognition of distinct T g determinants 
among H-2-differnet susceptible strains. Interestingly, the minimal 9 mer (2496-2504) Tg 
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epitope, causes EAT in k and s strains and it turns out that this peptide binds to both Ek 
and A8 molecules (Rao et al. 1994). Thus, there are also shared Tg determinants that are 
pathogenic in both H-2k and H-28 mice. 
hTg-derived pathogenic peptides 
Utilizing a cytotoxic T-cell hybridoma, Texier eta/. discovered the first pathogenic hTg 
peptide (1671-1710) in a trypsinized hTg fragment. This 40mer peptide caused EAT in 
CBA mice by direct challenge (Texier et al. 1992). Computerized algorithm methods 
have also been used in mapping immunopathogenic T-cell epitopes in hTg, taking 
advantage of the knowledge that the HLA-DR3 allele is associated with HT in humans 
(Ban and Tomer 2003). HLA-DR3-transgenic mice provided a wonderful tool to test the 
pathogenicity ofhTg peptides (Kong et al. 1996). By searching for HLA-DR3 binding 
sequences, Flynn et al. (Flynn et al. 2004) identified four immunogenic peptides (hTg 
181, hTg418, hTg1518, hTg2079) in hTg, while only two ofthem (hTg181, hTg2079) 
showed thyroiditogenicity. All four peptides elicited a significant proliferative response 
to hTg-primed cells from DR3+ transgenic mice, suggesting that these peptides are 
naturally generated by the processing ofhTg in vivo. Considering that HLA-DR is 
homologous to the mouse I-E molecule, these two peptides may also induce EAT in H-2k 
mice. In fact, one 16mer mTg peptide (179-194), overlapping the analogue sequence of 
15mer hTg peptide (181-195), showed immunopathogenicity in EAT when administered 
to CBA/J mice (H-2k) (Li and Carayanniotis 2006). In addition, an Ek-restricted hTg 
peptide (2340-2359), which was initially found encompassing B-cell epitope(s) 
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recognized by autoantibodies from Graves' disease sera (Thrasyvoulides et al. 2001 ), 
elicited autoimmune thyroiditis in AKR/J (H-2k) mice (Karras et al. 2003). Recently, its 
pathogenicity has been also described in HLA-DR3 transgenic mice (Karras et al. 2005). 
Pathogenic Tg peptides containing hormonogenic sites 
Based on the observation that iodine-deficient Tg fails to induce autoimmune thyroiditis 
in mice (Champion et al. 1987), it has been hypothesized that immunodominant epitopes 
might be iodinated peptides. Initial attempts to identify pathogenic iodinated 
determinants focused on the hormonogenic sites (Champion et al. 1991, Hutchings et al. 
1992, Kong et al. 1995, Wan et al. 1997). The 12mer peptide (2549-2560), having T4 at 
residue 2553, was first found to cause EAT in H-2k mice and was presented in the context 
of Ak (Champion et al. 1991, Hutchings et al. 1992, Kong et al. 1995, Wan et al. 1997). 
This peptide elicited EAT in recipient mice only by adoptive transfer of peptide-activated 
splenocytes, but not by direct challenge (Hutchings et al. 1992). It is noteworthy that 
p2549 was the first peptide found to be presented by the processing of intact Tg in vivo, 
since it was recognized by Tg-primed LNC (Kong et al. 1995). Another EAT -causing 
peptide (a.a.l-12) with T4 at a.a. residue 5 has also been identified (Kong et al. 1995). 
Like p2549, this peptide also elicited a cytotoxic T cell response (Wan et al. 1998). 
However, studies with peptides encompassing the other two hormonogenic sites showed 
that the peptides (2559-2570 and 2737-2748) with T4 at residues 2567 and 2746, 
respectively, lacked immunogenicity (Wan et al. 1997). These data illustrated that the 
bulky two-phenyl-ring side chain ofT4 per se is not sufficient to impart immunogenicity 
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to any given Tg peptide, and as expected, the amino acid backbone played a pivotal role 
(Wan et al. 1997). 
Another six pathogenic Tg peptides containing iodotyrosyl residues were recently 
identified by Li et al. (Li and Carayanniotis 2006). These six pathogenic peptides were 
localized outside ofhormonogenic sites ofTg and induced EAT in CBA/J mice (Li and 
Carayanniotis 2006). These results will be described in more detail in section 1.3.3. 
1.2.3 Use of computerized algorithms in mapping potential dominant epitopes in 
Tg 
To date, none of the 23 known pathogenic Tg peptides have been shown to encompass 
dominant determinant( s ). The conventional definition of dominant epitopes might not 
apply to determinants derived from Tg antigen due to its large size, but nevertheless, 
mapping potential dominant peptides within Tg is still possible. Further understanding of 
the processing ofTg by APC and parameters determining this process will be helpful in 
identifying dominant pathogenic Tg peptides. 
The theoretic basis of computerized algorithms 
Computerized algorithms stem from the findings that peptide binding to MHC molecules 
follows stringent rules according to different MHC isotypes (Allen et al. 1987, Sette et al. 
1987, Ogasawara et al. 1990, Kurata and Berzofsky 1990, Boehncke et al. 1993). Allen et 
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al. were the pioneers in studying the interaction between a peptide and a MHC molecule, 
and the interaction between TCR and a peptide-MHC complex (Allen et al. 1987). Using 
the hen egg lyzozyme (HEL) peptide 52-61, they demonstrated that certain a.a. residues 
served in the interaction between a MHC molecule, in this case A k, and HEL52-61, while 
other amino acid residues were responsible for TCR recognition. Numerous studies have 
confirmed that specific a.a. substitutions alter TCR contact or affect MHC binding 
affinity (Sette et al. 1987, Ogasawara et al. 1990, Kurata and Berzofsky 1990, Boehncke 
et al. 1993). Peptide sequences presented by the same MHC molecule, Ek or Ak, share 
binding motifs (Leighton et al. 1991, Altuvia et al. 1994). 
Compilation of Ak and Ek-binding motifs 
The computerized algorithm described by Altuvia et al. was used in identification ofTg 
peptides (Altuvia et al. 1994, Verginis et al. 2002, Li and Carayanniotis 2006). This 
algorithm was derived from a database of peptides, known to bind to A k or Ek molecules 
and elicit T -cell responses. It also characterized the common features within these groups 
of peptides. The motifs of peptides took into account the physic-chemical and structural 
properties of the amino acids such as hydrophobicity, charge, size and polarity that were 
essential for MHC binding. Three A k and five Ek -binding motifs were described in this 
study. 
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Early studies on searching dominant Tg epitopes by computerized algorithms 
So far, a total of 19 of23 Tg peptides have been identified using computerized algorithm 
approach (Chronopoulou and Carayanniotis 1992, Rao et al. 1994, Carayanniotis et al. 
1994, Rao and Carayanniotis 1997, Verginis et al. 2002, Flynn et al. 2004, Li and 
Carayanniotis 2006). In 2002, Verginis et al. systematically scanned the complete mTg 
sequence to detect dominant pathogenic T -cell epitopes by using A k- binding motifs 
(Verginis et al. 2002). This approach was justified by previous observations: 1) the 
autoimmune response to Tg and thyroiditis were under the genetic control ofthe 1-Ak 
subregion (Vladutiu and Zaleski 1981, Beisel et al. 1982); 2) administration ofanti-1-Ak 
Abs prevented EAT (Vladutiu and Steinman 1987). The above observations indicated 
that dominant epitope(s) might be presented in the context of Akin the susceptible H-2k 
strain. In this study, they identified five pathogenic peptides but none of them showed 
dominant characteristics. Verginis et al. found 99 additional Ak-binding sites in mTg and 
it remains, therefore, quite likely that dominant epitopes may be found in this subset and 
only a few of these A k -binding peptides may become immunodominant epitopes after the 
processing of intact Tg in APC in vivo and in vitro. 
Intracellular proteolysis ofTg 
The proteolysis ofTg is thought to occur in lysosomes following its uptake by 
macropinocytosis (Dunn and Dunn 2000). The investigation of the enzymes involved in 
degrading Tg showed that thyroid proteases were commonly found in lysosomes of most 
organs (Dunn and Dunn 2000). The following proteases may play an important role in 
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Tg degradation: cathepsin D (aspartic endopeptidase) (Dunn and Dunn 1982), cathepsin 
B, H, L, and S (cysteine endopeptidases) (Dunn et al. 1991, Nakagawa and Ohtaki 1984, 
Petanceska and Devi 1992) and two exopeptidases, dipeptidase I and dipeptidyl peptidase 
II (Dunn et al. 1996). In 1991, Dunn et al. (Dunn et al. 1991) investigated the cleavage 
sites ofTg by human cathepsins B, D, L. Three cleavage sites for cathepsin Band four 
for cathepsin D were found scattered within the Tg molecule, while four cleavage sites 
for cathepsin L were clustered at the C-terminal ofTg. Although the exact processing of 
Tg has not been well defined yet, the combined action of endopeptidases and 
exopeptidases is likely to generate some T -cell determinants but, at the same time, to 
destroy others. The limited Tg fragments produced via proteolysis are delivered to the 
assembly of MHC-II/peptide complexes at the end of endocytic pathway (Watts 1997). 
A clarifying insight is that T -cell determinants in a degraded antigen fragment are not 
randomly or equally captured by class II MHC molecules (Sercarz et al. 1993). 
Accumulated evidence has shown that not all antigenic determinants are efficiently 
presented forT-cell recognition (Maizels et al. 1980, Bixler et al. 1985, Shimonkevitz et 
al. 1984). Generally, only a few or one determinant(s)- the immunodominant ones, 
derived from the processing of a given antigen, elicit an antigen-specific T -cell response, 
while the rest of determinants are invisible to T -cells and are referred to as cryptic 
epitopes (Sercarz et al. 1993). 'A gradient of presentation effectiveness' comprises the 
stringent hierarchy of the epitopes within self-antigens, which determines which 
epitope(s) will be dominant or cryptic (Sercarz et al. 1993, Moudgil and Sercarz 2005). 
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The determinants undergoing appropriate processing will compete each other for binding 
effectively to MHC molecules (Sercarz 2002). In this competition, the first available 
determinant, close to a cleavage site, has been thought to have the priority (Gammon et al. 
1987, Moudgil and Sercarz 2005). This hypothesis, termed 'determinant capture', has 
been supported by several studies (Sercarz et al. 1993, Schneider et al. 2000). The 
processing of HEL provides examples of 'determinant capture' (Sercarz et al. 1993 ). 
Both NOD and BALB/c mice are good antigen-responders for HEL. Only the dominant 
HEL peptide (11-25) and subdominant HEL peptide (91-105) are known to elicit peptide-
specific T-cell responses in NOD mice. In addition, the Ed-restricted HEL peptide (106-
116) elicits a dominant T -cell response in BALB/c mice. Therefore, in (NOD x BALB/c) 
F1 mice, codominant responses to peptide (11-25) and peptide (106-116) were observed 
as expected. However, the subdominant response to peptide (91-105) was totally 
abrogated. Strikingly, when these mice were challenged with cyanogens bromide 
(CNBr)-treated HEL, which was cut at a.a. position 12 and 105, a significant response to 
p(91-105), equivalent to other dominant peptides, was unmasked. They concluded that 
the dominance of peptide (91-105) revealed here, was due to the precise scission that 
exposed the determinant (91-105) as the first accessible binding motif(Sercarz et al. 
1993). Furthermore, by introduction of an endopeptidase cleavage site in HEL, Schneider 
et al. demonstrated enhancement of presentation of a determinant adjacent to the 
cleavage site (Schneider et al. 2000). The above studies highlight that the dominant 
determinants for a given antigen, may occur adjacent to the endopeptidase cleavage sites. 
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Based on the above findings, we hypothesize that the dominant determinants ofmTg may 
be A k -restricted and may be found in the regions close to the endopeptidase cleavage sites. 
In chapter 4, we describe a theoretical prediction of dominant epitopes in mTg by using 
computerized algorithm to search for A k -binding site adjacent to cathepsin cleavage sites 
inmTg. 
1.3 The effect of iodine on autoimmune thyroiditis 
1.3.1 Iodine metabolism 
Iodine is an indispensable component of thyroid hormones, T3 and T4, constituting 59% 
and 65% of their molecular weight, respectively (Dunn and Dunn 2001 ). Therefore, 
iodine metabolism is of great relevance to hormone formation. Basically, the formation of 
T3 and T4 contains following steps: 1) active uptake of iodide; 2) formation of 
iodotyrosyl residues ofTg; 3) coupling ofiodotyrosyl residues to form T3 and T4; 4) 
proteolysis ofTg to release hormones; 5) deiodination ofiodotyrosines and recirculation 
of iodide (Taurog 2000). 
To utilize iodide, thyroid follicular cells first actively transport iodine against an 
electrochemical gradient from plasma to the cytoplasm (Wolff 1964). This process of 
crossing the basolateral plasma membrane of the follicular cells is mediated by the Na+/r 
symporter (NIS) and consumes cellular ATP (O'Neill et al. 1987). The thyroid 
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stimulating hormone (TSH) has been considered as one of the most important regulators 
for r transport since TSH upregulates NIS protein expression (Levy et al. 1997, 
Uyttersprot et al. 1997). The other well known regulator is iodide itself (Wolff and 
Chaikoff 1948). Either high doses or low doses of iodide inhibit the accumulation of 
iodide in the thyroid (Braverman and Ingbar 1963, Eng et al. 1999). Intracellular iodide 
passively passes through a putative r channel to the apical membrane where it is oxidized 
for further utilization (Dunn and Dunn 2001 ). 
Once iodide is translocated into the follicular lumen, the second step, iodination ofTg, 
occurs, mediated by thyroid peroxidase (TPO) (Taurog 1964). Except TPO, H202 and 0 2 
as the oxidizing agents are also necessary for iodination (Taurog 1964). TPO has two 
substrate sites, one favoring iodine and the other favoring tyrosine. The reaction ofTg 
iodination starts with the oxidation of TPO by H20 2, then oxidation of iodine and 
tyrosine. The corresponding free radicals, the iodinium ion (t) and hypoiodite (Or) 
yielded from the above oxidation reactions attach to each other to form monoiodotyrosine 
(MIT) or diiodotyrosine (DIT). Within the Tg molecule, further oxidation occurs, 
resulting in the formation ofT4 and T3 by coupling two DIT residues or one DIT and one 
MIT (Taurog 2000). The tyrosyl residues in Tg are not equally susceptible to iodination 
(Dunn and Dunn 1999). Generally, the favored sites for hormone formation, also named 
as hormonogenic sites, are residues 5, 2553,2567 and 2746. (Dunn and Dunn 1999). 
However, many other tyrosyl residues are also capable of incorporating of iodine (Marriq 
et al. 1989, Ohmiya et al. 1990). 
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Further release ofT4 and T3 requires iodinated Tg reentry into the thyroid cells (Dunn 
and Dunn 2001). Tg is internalized by macropinocytosis initially fuses with early 
endosomes, then with lysosomes, where the proteolytic degradation ofTg and hormone 
liberation take place (Dunn and Dunn 2001). Finally, the released hormones T4 and T3 
are secreted to the circulation. The iodotyrosine residues removed from Tg undergo 
deiodination by an iodotyrosine-specific deiodinase in follicular cells and their released 
iodide is reused for hormone synthesis (Rosenberg and Goswami 1979). 
1.3.2 Iodine excess with AT 
It has been widely accepted that high iodine intake is associated with the onset and 
development of AT (Boumaud and Orgiazzi 2003). This conclusion is based on the 
accumulated evidence both from epidemiological and experimental studies (Boumaud 
and Orgiazzi 2003). Epidemiological studies show an increasing incidence ofHT during 
the implementation of iodine prophylaxis, that is food supplementation with iodine to 
prevent endemic goiter in iodine-deficient areas (Boumaud and Orgiazzi 2003 ). A 
comparative epidemiological study was examined in two populations, in Jutland where 
iodine intake was relatively lower ( 40-80 J.tg/day) than the recommended daily iodine 
requirement of 150 J.lg and in Iceland where iodine intake was much higher with a the 
median urinary iodine excretion rate of 300 J.tg/day (Laurberg et al. 2000). High incidence 
ofhypothyroidism was found among elderly subjects in Iceland, 3.9% in females and 
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0.6% in males. However, hypothyroidism was uncommon in the same age groups in 
Jutland. Also, the investigations in the high iodine intake areas such as Japan, Whickham 
and Worcester suggested the increase ofHT in parallel with the increase of iodine in the 
diet (Robuschi et al. 1987, Vanderpump et al. 1995). In addition to a moderate increase in 
iodine level by a persistently long period of exposure, a short-term exposure to large 
doses of iodine contained in certain drugs such as amiodarone also leads to iodine excess 
(Roti and Vagenakis 2000). 
Studies on animal models have provided a more clear profile of the effect of iodine on 
induction and development of AT. Bagchi et a/. demonstrated that excess dietary iodine 
enhanced the incidence of AT in the Cornell strain (CS) chicken (Bagchi et al. 1985). 
They fed the CS chickens with different concentrations of KI -containing water during the 
first 10 weeks of life. Then, AT induction was accessed by examining lymphocytic 
infiltration of thyroid glands and the presence of anti-Tg, T3 and T4 antibodies. About 
7.3% of the chickens treated with excess iodine developed AT. However, in the normal 
iodine intake group, only 1.28% of the chickens had AT. Moreover, the OS chickens, 
raised under conditions of iodine-deficiency, had a dramatically decreased incidence of 
thyroid autoantibodies. Similar results were observed in other animal models such as the 
BB-DP rat (Mooij et al. 1993). Mooij et al. administered an enriched iodine diet (EID 
100 JJg iodine /day) or a normal iodine diet (NID 7 JJg iodine /day) to young BB rats(< 3 
wk old) for 18 weeks (Mooij et al. 1993). About 50% ofBB rats fed with 100 JJg iodine 
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per day developed the focal lymphoid cell infiltrates in the thyroids, suggesting high 
iodine intake accelerates the development of AT. 
While the mechanisms by which iodine excess influences thyroid autoimmune reactivity 
are not clear, three possible mechanisms have been proposed (Ruwhof and Drexhage 
2001 ). 1) Iodine excess may have toxic effect on thyrocytes, resulting in thyrocyte 
damage directly (Li and Boyages 1994, Many et al. 1995). 2) Iodine could stimulate 
immune cells such as dendritic cells, macrophages and T cells to facilitate the 
development of autoimmune response (Toussaint-Demylle et al. 1990, Li et al. 1993). 3) 
The incorporation of iodine increases the immunogenicity ofTg (Carayanniotis 2003). In 
the next section, we will focus on studies related to the last hypothesis. 
1.3.3 Iodination increases Tg immunogenicity 
It has been suggested that iodination ofTg enhances its immunogenicity (Ruwhofand 
Drexhage 2001, Carayanniotis 2003). In 1992, Ebner et al. examined the Ab responses 
against Tg with different iodine content in BBIW rats immunized with normally iodinated 
Tg (NT g) or low iodine Tg (LTg) (Ebner et al. 1992). The NTg or L Tg was obtained 
from thyroid glands of rats that were fed with a normal diet or an addition of 0.5% 
methimazole which inhibits the conversion of iodide to iodine by binding to TPO. They 
found that 31% of the BBIW rats immunized with NTg showed significant thyroidal 
lymphocytic infiltration, while none ofthe BBIW rats in the LTg-immunized group 
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developed lymphocytic thyroiditis. In addition, higher levels of anti-Tg antibodies were 
detected in the NTg-challenged rats compared to the LTg-challenged rats, indicating that 
iodination increases the immunogenicity ofTg. Similar results had been observed in CS 
chickens and mice (Sundick et al. 1987, Dai et al. 2002). Using CS chickens, Sundick et 
al. demonstrated that highly iodinated Tg (about 60 iodine atoms /Tg) elicits a stronger 
anti-Tg response than low iodinated Tg (Sundick et al. 1987). Later, Dai et al. (Dai et al. 
2002) investigated the immunogenicity ofTg with 15-20 iodine atoms or 55-70 iodine 
atoms in SJL strain mice. More severe EAT was induced in mice immunized with high-
iodinated Tg (55-77 iodine atoms) than mice immunized with normal Tg (15-20 iodine 
atoms). Moreover, the LNC from high iodinated Tg-primed mice proliferated vigorously 
in the presence ofhigh-iodinated Tg, but mildly in the presence of normal Tg. 
In regard to the underlying mechanisms of the enhanced immunogenicity ofTg induced 
by iodination, it is likely that iodination modification of Tg results in the formation of 
neo-epitopes containing iodothyronines I iodotyrosines and generation of non iodinated 
pathogenic epitopes that are normally cryptic to the immune system (Carayanniotis 2003). 
These epitopes may break the established T-cell tolerance, leading to autoimmune 
thyroiditis. 
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The first iodinated T-cell epitope (2551-2559) containing T4 at position 2553 was 
identified by Champion et al. (Champion et al. 1991). Using two clonal T-cell 
hybridomas, they demonstrated that recognition of this epitope required the presence of 
the T4 residue, since substitution ofT4 iodothyonine at position 2553 with any other 
amino acids abrogated the ability of the peptide to stimulate the T -cell hybridoma clones. 
Studies on the pair of analogue peptides (2549-2560) carrying TO or T4 provided further 
understandings on the role of iodine in the formation ofT -cell determinants (Kong et al. 
1995). The peptide TO (2553), lacking four iodine atoms at position 2553 was 
immunogenic in CBA mice and induced EAT by adoptive transfer of TO-primed LNC in 
recipients, suggesting that the immunogenicity of TO (2553) depends on the amino acid 
backbone not iodine atom modification. In this study, they also found that T4 (2553)-
primed LNC could be stimulated by T4 (2553) but could not be cross-stimulated by TO 
(2553). This finding indicated iodine modification was sufficient to recruit a distinct 
subset ofT-cells which only recognizes only iodine-modified epitope. 
Another possible mechanism of the enhanced immunogenicity of the iodinated Tg is that 
iodine modification changes the processing ofTg in APC, thus rendering the generation 
of normally cryptic epitopes (Dai et al. 2002, Carayanniotis 2003). Tg peptide (2494-
2510) has shown crypticity features in SJL mice (Chronopoulou and Carayanniotis 1992). 
However, LNC from highly iodinated Tg (HI-Tg) containing 55-70 iodine atoms per 
monomeric subunit proliferated well in the presence ofp2494. Additionally, p2494-
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specific T-cell clonal hybridomas were significantly activated by processing of HI-Tg in 
macrophages or dendritic cells in vitro. Therefore, the iodination ofTg converted the 
cryptic p2494 into a dominant determinant. 
In a recently published study, Li. et al. identified six pathogenic Tg peptides with 
iodotyrosyl residues out ofhormonogenic sites (Li and Carayanniotis 2006). Strikingly, 
three Tg peptides, peptide I-p117 (a.a.117-132), peptide I-p304 (a.a 304-318) and peptide 
I -p 1931 (a. a. 1931-1945) were immunopathogenic only in their iodotyrosyl-containing 
form in CBA mice. The iodotyrosine residue facilitated binding ofl-p304 and I-p117 to 
A k' while the iodotyrosine residue of I -p 1931 may constitute a central contact residue for 
TCR. These results illustrate that neo-antigenic determinants formed via iodine 
modification of Tg peptides cause thyroiditis. However, further studies with additional 
Tg peptides indicated that iodine modification does not always enhance the 
immunogenicity of Tg peptides. By comparing iodinated peptides with their non-
iodinated analogs, we found that iodination increased the immunogenicity of p 179 (a. a. 
179-194), decreased the immunogenicity ofp2540 (a.a. 2540-2554) and did not alter the 
immunogenicity ofp2529 (a.a. 2529-2545) (unpublished data). These findings provided, 
for the first time, evidence for differential influences of iodination on immunogenicity of 
Tg T-cell determinants. Iodination might regulate the immune response to Tg by 
enhancing the immunogenicity of some Tg peptides, while simultaneously decreasing the 
immunogenicity of other Tg peptides. This process is perhaps mediated by the influence 
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of iodine atoms on peptide MHC binding or T-cell recognition. However, these 
observations do not contradict earlier studies that iodination increases Tg 
immunogenicity (Dai et al. 2002, Sundick et al. 1987). This effect can be explained as a 
consequence ofthe total influences ofiodotyrosyl formation on Tg determinants. 
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CHAPTER2 
MATERIALS AND METHODS 
2.1 Animals 
Female CBA/J (H-2k) mice purchased from Jackson Laboratories (Bar Harbor, ME) were 
used in experiments at 6-8 weeks of age. 
2.2 Antigens 
2.2.1 Purification of mTg 
mTg was extracted from thyroids of outbred ICR mice (Bioproducts for Science, 
Indianapolis, IN) as previously described (Chronopoulou and Carayanniotis 1992). 
Briefly, frozen glands (Bioproducts for Science, Inc., Indianapolis, IN) were 
homogenized in phosphate buffer (pH 7.0) with protease inhibitors: Leupeptin (10-6 
mol/L), Pepstatin A (10-5 mol/L) PMSF (10-3 mol/L) and the supernatant was centrifuged 
three times at 14,000 rpm. mTg was obtained from the supernatant by passing through a 
Sepharose CL-4B column (Pharmacia, Baie d'Urfe, Quebec, Canada). The fractions of 
peak II (Figure 2.1) were pooled, dialyzed in double distilled water (Fisher Chemicals) 
three times, then concentrated to 3-5 mg/ml by ultra-filtration cells (Amicon, Danvers, 
MA), filter-sterilized, lyophilized and stored at -20°C. Tg concentration was assessed 
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spectrophotometrically (O.D.2so) and calculated as the molarity of the monomeric form 
(330 kDa, lOQ ~g/ml = 0.303 ~M). 
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Figure 2.1 Purification ofmTg. 
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One hundred frozen thyroid glands from outbred ICR mice were homogenized in 2.5 ml 
ice-cold PBS containing protease inhibitors (Leupeptin, Pepstatin A, PMSF). The 
supernatant was loaded on the Sepharose column following centrifugation (14,000 rpm, 
10 min). Tg was collected in tubes (3.3 ml/tube) and its concentration was measured 
spectrophotometrically at 280 nm. The fractions of peak II from tubes 19 to 28 (62.7 ml 
to 92.4 ml in the figure) were pooled together, dialyzed three times in double distilled 
water, concentrated, filtered and lyophilized. The Tg powder was stored at -20°C. 
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2.2.2 Peptides 
The Tg peptide (179-194) NTTDMMIFDLIHNYNR (p179), its iodinated form I-p179 
(NTTDMMIFDLIHNY(I)NR) and I-p304 (a.a 304-318) were synthesized at >80% purity 
at the Dalton Chemical Laboratories Inc. (Toronto, Ontario, Canada). All truncated 
peptides (>90% purity) were synthesized at Biosynthesis, Inc. (Lewisville, TX). mTg 
peptide (a.a. 2496-2504), p2496 (Rao et al. 1994) used in the studies was previously 
synthesized at the Alberta Peptide Institute (Edmonton, Alberta, Canada) and peptide (a.a. 
1826-1835), p1826 (Verginis et al. 2002) was synthesized by Sigma-Genosys (The 
Woodlands, TX). All peptides were blocked with an acetyl group at theN-terminal and 
with an amide group at the C-terminal end. 
2.3 Proliferation assay of antigen-specific LNCs 
Mice were immunized s.c with 100 nmol Tg peptide p 179 or 100 !Jg mTg in CF A (with 
Mycobacterium butyricum; Difco Laboratories). Nine days later, the inguinal, brachial, 
and axillary lymph node cells were cultured (5 x 105 cells /well) for 4 days with or 
without Ag in 200 ).11 microculture. Eighteen hours before harvesting, 1 ).lCi eH] 
thymidine (PerkinElmer, Life and Analytical Sciences, Boston, MA) was added to each 
well. The cells were harvested 18 h later by a Harvester 96® Mach III M (Tomtec, 
Hamden, CT, USA) and radioactivity incorporation was counted in the Topcount 
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NXTTM microplate counter (Canberra Packard Canada, Mississauga, ON, Canada). 
Stimulation index is defined as ( cpm in the presence of Ag)/( cpm in the absence of Ag). 
2.4 Cell culture 
2.4.1 Cell lines and culture media 
Cell culture was performed in Dulbecco's Modified Eagle Medium (DMEM) (Invitrogen 
Life Technologies) supplemented with 10% fetal bovine serum (FBS) (Cansera, Ontario, 
Canada), 20 mM HEPES buffer, 2 mM L-glutamine, 100 U/ml penicillin, 100 J.tg/ml 
streptomycin (all from Invitrogen Life Technologies), and 5 X 10-5 M2-ME (Sigma-
Aldrich, St. Louis, MO) (complete medium). The antigen presenting cell line LK35.2 (H-
2Akld, H-2Ek/d) (Kappler et al. 1982), the IL-2 dependent cell line CTLL (Gillis and Smith 
1977) and hybridomas specific for Ak (10-3.6.2, IgG2a) (Oi et al. 1978), Ek (14-4-4s, 
IgG2a) (Ozato et al. 1980) and influenza A nucleoprotein (H16-L10-4R5, IgG2a) 
(Y ewdell et al. 1981) were purchased from the American Type Culture Collection 
(Manassas, VA). The respective monoclonal antibodies were purified from culture 
supernatants by affinity chromatography on a protein G-Sepharose 4 Fast Flow Column. 
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2.4.2 Generation of peptide-specific T -cell hybridoma clones 
The IL-2-secreting T cell hybridomas 1E7, 4A11, 2D5, 1B3 and 2H2 were generated 
following a modified method described by Perkins eta/. (Perkins et al. 1991). Briefly, 
CBA mice were challenged s. c. with 100 nmol p179 or I-p179 in 100 J..ll ofPBS/CFA 
emulsion and nine days later, draining LNCs were collected and 4 x 106 cells/ml were 
cultured in the presence of 20 J.!M of the respective peptides. After three days, the 
stimulated cells were fused at a 1:2 ratio with BW5147a-~-lymphoma cells (White et al. 
1989) by using polyethylene glycol (Boehringer Mannheim, Indianapolis, IN). 
H ybridomas appeared after 7-10 days of culture initially with HAT -containing medium 
(Sigma), then HT-containing medium (Sigma), and then finally normal complete medium. 
The specificity and sensitivity of the hybridomas were screened by an activation assay as 
described in the following paragraph. Peptide-specific hybridomas were cloned by 
limiting dilution at 0.3 cell/well in complete medium containing 20% FBS with 1% 
syngeneic red blood cells (RBC) used as feeder cells. 
2.4.3 Activation assay ofT -cell hybridomas 
An activation assay of clonal T -cell hybridomas was performed by incubating hybridoma 
cells (105 cells/well) and LK35.2 cells (105 cells/well) in the presence of relevant peptides. 
After 24 hours of incubation, 100 J..ll of supernatant was transferred from each well into 
new plates and stored at -70°C for at least 2 hours. The release ofiL-2 in the culture 
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supernatant was assessed by measuring the proliferation of the CTLL cells. In brief, 104 
CTLL cells per well were cultured in the above supernatant. After 18 h, 1 f.lCi of eH]-
thymidine was added to each well. The cells were harvested 6 h later as described in 2.3. 
2.5 MDC-restriction analysis ofT -cell hybridomas or T -cells from peptide-primed 
LNCs 
2.5.1 Blocking assay ofT-cell hybridomas or T-cells from peptide-primed LNCs 
The blocking assay was used to determine the MHC-restriction ofT -cell hybridoma 
clones or T-cells from peptide-primed LNC. Hybridoma cells (105 cells/well) were 
incubated with a constant amount of their respective ligands, LK35.2 cells (105 cells/well) 
and serial dilutions of the blocking Abs in a 200 f.ll final volume. After 24 hours, 100 f.ll 
of supernatant was transferred to a new plate from each well, then frozen at -70°C for at 
least 2 hours. The IL-2 secretion was determined by CTLL assay as described in 2.3.3. 
To perform blocking assay of peptide-primed LNCs, CBA/J mice were immunized with 
100 nmol ofp179 or I-p179 emulsified in CFA and nine days later, draining LNCs 
proliferative responses to priming peptides were assessed in the presence of anti-I-Ak or 
anti-I-Ek Abs, as described in section 2.3. 
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2.5.2 Competitive inhibition assay ofT -cell hybridoma activation 
T-cell clones 10Cl.8 (1-Ak-restricted, l-p304-specific) (Li and Carayanniotis 2006) and 
8F9.27 (I-Ek-restricted, p2496-specific) (Rao et al. 1994) were used in the competitive 
inhibition assay to determine the MHC-restriction of p 179 and its iodinated analogue. In 
a flat-bottom microwell plate, 105 of 1 OC 1.8 or 8F9 .27 cells were cultured with a 
constant amount of relevant ligand, serial dilutions ofp179 and I-p179 as competitive 
inhibitors and 105 LK35.2 as APC. The supernatant (100 !J.llwell) was collected in a new 
plate after 24 hours of incubation, then frozen at -70°C for at least 2 hours. The IL-2 
secretion was determined by CTLL assay as described in 2.3.3. 
2.6 Analysis ofT-cell receptor (TCR) V-fJ family utilization of peptide-specific 
T -cell hybridomas 
2.6.1 RNA extraction 
Total RNA was extracted from 5 x 106 ofT cell hybridomas using TRIZOL 
reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's instruction. 
Briefly, cells were lysed in 1 rnl ofTRIZOL reagent, and then 200 J..Ll of 
chloroform (Sigma Chemicals) was added for the phase separation. The solution 
was separated into an upper aqueous phase containing RNA and an organic phase 
by centrifugation. The aqueous phase (about 600 !J.l} was transferred in a new 
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diethylpyrocarbonate-treated tube and RNA was recovered by precipitation with 
isopropylalcohol (500 J .tl). The RNA pellet was washed with 1 ml of70% ethanol, 
air-dried and dissolved in 20 ~l ofRNase-free water (Sigma Chemicals). The RNA 
yield and its purity were measured using a Beckman Du®64 spectrophotometer 
(Fullerton, CA, USA) at the optical density (O.D.) of260 and 280 nm. The RNA 
with purity from 1.6 to 1.8 (260 nm/280 nm) was chosen for further RT-PCR 
analysis. 
2.6.2 eDNA synthesis 
First-strand eDNA synthesis was performed using a cNDA synthesis kit (Amersham 
Bioscience, Buckinghamshire, UK). Briefly, 5 ~g oftotal RNA was heated at 65°C for 10 
min to remove RNA secondary structure, and then chilled on ice. The denatured RNA 
was added to a mixture containing 11 ~1 first-strand bulk mix, 1 ~1 dithiothreitol (DTT) 
solution and 0.2 ~g Notl-d(T)18 primer (1 ~1). FPLCpure™ murine reverse transcriptase is 
already contained in the first-strand bulk mix. The total 33 ~1 reaction solution was then 
incubated at 37°C for 1 hour and terminated by heating at 75°C for 10 min. The eDNA 
was stored at -20°C. 
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2.6.3 PCR amplification 
First strand eDNA was amplified by PCR in a reaction mixture containing: 1 x PCR 
buffer, 1.5 mM MgCb (Invitrogen, Carlsbad, CA, USA), 0.2 mM of each dNTP (Gibco-
BRL), 2 f..ll eDNA template, 20 pmoles of each primer (forward and reverse, Operon 
Technologies, Inc. Alameda, CA, USA) (Table 2.1), 2.5 U Taq polymerase (Invitrogen) 
and RNase-free water (Sigma) to 100 f..ll final volume. Forward primers specific for Vj3 
families and a reverse primer specific for Cj3 were chosen as described (Casanova et al. 
1991). Mineral oil was added to the top ofthe PCR solution to avoid evaporation. A 35-
cycle step program (1 min denaturation at 95°C, 1 min annealing at 55°C, and 1 min 
extension at 72°C) was performed on the Perkin Elmer DNA thermocycler (Cetus, 
Norwalk, CT, USA) with a preceding 5 min denaturation step at 94°C followed by 10 
min extension step at 72°C. The PCR products were visualized by 1.5% agarose gel 
electrophoresis containing 0.5 f..lg/ml ethidium bromide. 
2. 7 Statistical Analysis 
Data were analysed by t test using the GraphPad Prism software. 
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Table 2.1 PCR primers used in this study 
primer Sequence (5'~3') PCR product (bp) 
(VB +CB) 
cp CCAGAAGGTAGCAGAGACCC 
VP1 CCCAGTCGTTTTATACCTGAATGC 350 
VB2 TCACTGATACGGAGCTGAGGC 322 
VB3 CCTTGCAGCCTAGAAATTCAGTCC 317 
VP4 GCCTCAAGTCGCTTCCAACCTC 364 
VB5.1 GTCCAACAGTTTGATGACTATCAC 334 
VB6 CTCTCACTGTGACATCTGCC 306 
VP7 TACAGGGTCTCACGGAAGAAGC 346 
VP8.1 CATTCTGGAGTTGGCTTCCC 305 
VB8.2 CCTCATTCTGGAGTTGGCTACCC 303 
VP8.3 ACGCAAGAAGACTTCTTCCTCCTGC 335 
VB9 TCTCTCTACATTGGCTCTGCAGGC 308 
VP10 ATCAAGTCTGTAGAGCCGGAGGAC 300 
VPll GCACTCAACTCTGAAGATCCAGAGC 315 
vp12 GAAGATGGTGGGGCTTTCAAGGATC 366 
VP13 AGGCCTAAAGGAACTAACTCCAC 386* 
VP14 ACGACCAATTCATCCTAAGCAC 317 
VB15 CCCATCAGTCATCCCAACTTATCC 343 
VB16 CACTCTGAAAATCCAACCCAC 312 
VPI7 GAGTAACCCAGACTCCACGA 522 
VJH8 CAGCCGGCCAAACCTAACATTCTC 333 
GAPDH (F) CCATCACCATCTTCCAGGAG 577 
GAPDH(R) CCTGCTTCACCACCTTCTTG 
*PCR product ofV/D2/J2.1/C sequence 
The above PCR primers were described by Casanova et al. (Casanova et al. 1991). 
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CHAPTER3 
EFFECTS OF IODOTYROSYL FORMATION ON T -CELL RECOGNITION OF 
A SINGLE THYROGLOBULIN PEPTIDE 
3.1 Abstract 
We have previously shown that iodotyrosyl formation within certain thyroglobulin (Tg) 
peptides confers to them immunopathogenic properties. In this study, we focused on the 
subdominant 16mer Tg peptide p179 (aa.179-194). Iodotyrosyl formation at the Y192 
residue enhances the immunogenicity but not the pathogenicity of p 179 but the 
mechanisms underlying this observation are not understood. This peptide has both A k-
and Ek-binding sites, and iodination was found not to alter this MHC-restriction profile. 
We developed a panel of p 179-specific T -cell hybridoma clones, with the view to 
examining the effects of a single iodine atom on T-cell recognition. Two Ek-restricted 
clones, 2H2 and 1B3, responded well to both p179 and I-p179 analogs, indicating that the 
bulky iodine atom did not sterically hinder their TcR engagement. Two other clones, 1E7 
(Ek -restricted) and 2D5 (A k-restricted) recognized only p 179, indicating a negative 
influence of the iodine atom on TcR recognition. Lastly, the Ek-restricted clone 4A11 was 
reactive only to I-p179, suggesting that the iodine atom is an integral part of its TcR 
ligand. Truncation analysis localized the determinant seen by all clones within the 11mer 
peptide p184 (aa. 184-194) suggesting that the cross-reactive clones were not activated 
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by a minimal epitope lacking Y192, and that the negative influence of iodine on 1E7 and 
2D5 was not due to effects from flanking residues. Taken together, these results 
demonstrate, at the clonal level, differential effects of a single iodine atom on the 
recognition of a single Tg peptide. Even when a net combined effect is discernible 
polyclonally this may not be associated with thyroidal damage, if various p179-specific 
clones do not contribute equally to pathogenicity. 
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3.2 Introduction 
Excessive iodine intake has been associated with the incidence of autoimmune thyroiditis 
in clinical and experimental studies (Braverman et al. 1971, Bagchi et al. 1985, Boyages 
et al. 1989, Robuschi et al. 1987, Tajiri et al. 1986, Mooij et al. 1993, Kahaly et al. 1998). 
The mechanisms underlying this association remain unknown but they may be, at least in 
part, related to the immunogenicity of thyroglobulin (Tg), the only molecule that 
incorporates iodine in vivo to facilitate the synthesis of the thyroid hormones 
triiodothyronine (T3) and thyroxine (T4) (Taurog 1964). Tg represents up to 75% of the 
total protein in the thyroid gland (Malthiery et al. 1989) and it is the major thyroid 
autoantigen causing experimental autoimmune thyroiditis (EAT), a T -cell mediated 
disease (Braley-Mullen et al. 1985, Flynn et al. 1989, Conaway et al. 1989), considered to 
be a model for Hashimoto's thyroiditis (HT) in humans (Rose and Witebsky 1956, Rose 
et al. 1971 ). 
Several studies have supported the view that the iodine content in Tg, which varies 
according to dietary intake, can influence its immunogenicity (Ebner et al. 1992, 
Champion et al. 1987, Sundick et al. 1987). For example, iodine-deficient Tg fails to 
induce EAT in mice (Champion et al. 1987) and BB/W rats (Ebner et al. 1992) and 
conversely, highly iodinated Tg is more immunogenic than normal Tg and elicits severe 
EAT (Dai et al. 2002, Sundick et al. 1987). Iodination has been shown to enhance Tg 
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immunogenicity by two ways: 1) by formation of neoantigenic determinants 
encompassing either hormonogenic or iodotyrosyl-containing sites (Kong et al. 1995, Li 
and Carayanniotis 2006); and 2) by alteration ofTg processing resulting in generation of 
non iodinated but pathogenic cryptic epitopes (Dai et al. 2002, Carayanniotis 2003). We 
have previously reported that iodotyrosyl formation can render certain innocuous Tg 
peptides (p304, p 117 and p 1931) immunopathogenic (Li and Carayanniotis 2006). 
Additional results, however, have suggested that iodotyrosyl formation can have variable 
effects on the immune recognition of other Tg peptides i.e. it can increase, decrease or 
not alter their established immunogenicity (Li and Carayanniotis 2006). In this study, we 
have used as a model antigen the mouse Tg peptide p179 (aa 179-194) because oftwo 
interesting features: a) an overlapping peptide analog (aa 181-195) has been reported to 
result from the natural processing of human Tg in HLA-DR3-transgenic mice (Flynn et al. 
2004); and b) the iodinated analog I-p179, carrying an iodotyrosyl at position Yl92, 
elicits stronger proliferative T cell responses than p179, but remains, unexpectedly, 
mildly pathogenic as p179. (Li et al. submitted for publication). Therefore, we aimed to 
examine ifp179 could be similarly generated following the in vivo processing ofmTg 
and, in addition, investigate at the clonal T -cell level, effects of a single iodine atom on 
T -cell recognition of p 179 that may account for the immunopathogenic behavior of the 
iodinated analog. 
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3.3 Results 
3.3.1 p179 contains subdominant epitope(s) 
We first tested whether the Tg peptides p179 and I-p179 contain dominant T-cell 
epitope(s). CBA/J mice were immunized with 100 J.tg ofmTg emulsified in CFA and 
nine days later, draining LNCs were cultured in the presence ofmTg or free peptides. Tg-
primed LNCs responded strongly against mTg (S.I. = 2.9- 8.2 in the 0.01- 1 !JM range), 
weakly to higher concentrations ofp179 (S.I .= 3.2 +/- 0.3 at 27 !JM), but failed to 
respond to equimolar amounts ofl-p179 (Figure 3.1A). Conversely, in vivo priming with 
p179 (100 nmol) elicited strong recall responses to the priming peptide (S.I. = 3.6- 14.7 
in the 0.6- 5 !JM range) and a weak but significant response (S.I. = 4.3-5.5) to equimolar 
amounts of mTg in vitro (Figure 3.1B). In all assays, proliferative LNC responses were 
not detected against the control Tg peptide p2496 (data not shown). These data indicate 
that p179 encompasses subdominant T-cell determinant(s). 
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Figure 3.1 p179 contains subdominant epitope(s). CBNJ mice (three mice per group) 
were challenged with either Tg (A) or p179 (B). Antigen-specific proliferation ofLNCs, 
in the presence of Tg (0 ), p 179 ( o) or I -p 179 ( •) was examined 9 days later. Data show 
the mean± SD ofS.I. values of triplicate wells and are representative of2-3 experiments. 
Background cpm varied from 3499 to 5653. 
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3.3.2 p179 and I-p179 can be presented in the context ofEk and Ak 
Tg peptide 179 (a.a. 179-194) was identified by scanning the mTg sequence (Kim et al. 
1998) for A k binding motifs with tyrosine as the flanking residue as seen in the previous 
study (Li and Carayanniotis 2006). Coincidentally, we found that this peptide also has an 
Ek -binding motif (Altuvia et al. 1994) (Figure 3.2A). To test whether p 179 and I-p 179 
could be presented in the context ofEk and Ak, we performed blocking assay using 
peptide-primed LNC. CBA/J mice were immunized with 100 nmol ofp179 or I-p179 
emulsified in CF A and nine days later, draining LNCs proliferative responses to priming 
peptides were assessed in the presence of anti-I-Ak or anti-I-Ek Abs. The proliferation of 
p179-primed LNC to 10 !JM ofp179 was significantly inhibited(% inhibition= 76.96 +/-
14.67, p<0.05) in the presence of 1.25 !Jg/ml anti-I-Ek Ab (Figure 3.2B). The same 
concentration of anti-I-A k Ab suppressed by 42.13 +/- 8.58% (p<0.05) the proliferative 
response ofp179-primed LNC to p179 (10 !JM) (Figure 3.2B). On the other hand, the 
proliferation ofl-p179-primed LNC to 10 !JM I-p179 was significantly inhibited(% 
inhibition= 86.02 +/- 3.86, p<0.05) in the presence of 1.25 jlg/ml anti-I-Ek Ab (Figure 
3.2C). The same concentration ofanti-I-Ak Ab suppressed by 36.71 +/-7.79% (p<0.05) 
the proliferative response ofp179-primed LNC to p179 (10 !JM) (Figure 3.2C). These 
data indicate that p 179 and I -p 179 can be presented in the context of A k and Ek, and the 
majority ofT-cells recognize this pair ofpeptides in the context ofEk. 
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Figure 3.2 p179 & I-p179 can be presented in the context ofEk and Ak. 
A, amino acid sequence ofp179. Ak binding motif(underlined) and Ek binding motif 
(bold) were identified following the algorithms described by Altuvia et al. (Altuvia et al. 
1994), Ak-binding motif A and Ek-binding motifC, respectively (Altuvia et al. 1994). B 
p179-primed LNC proliferative response to 10 J..LM p179 in the presence of anti-I-Ek or 
anti-I -A k blocking Abs ( 1.25 J..Lg/ml). C. I -p 179-primed LNC proliferative response 10 
J..LM I-p179 in the presence of anti-I-Ek or anti-I-Ak blocking Abs (1.25 )lg/ml). Anti-
influenza A nucleoprotein Ab was used as an isotype control for anti-I-Ek or anti-I-Ak 
blocking Abs.% inhibition= [1- proliferation with blocking Ab (cpm)/proliferation 
without blocking Ab (cpm)] x 100% 
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3.3.3 Iodination ofp179 does not influence MHC binding 
To determine whether iodination ofp179 can influence its binding to MHC, we used two 
hybridoma clones: the Ek-restricted 8F9 clone, specific for the Tg peptide p2496 (Rao et 
al. 1994) and the Ak-restricted lOCI clone, specific for the Tg peptide I-p304 (Li and 
Carayanniotis 2006) in order to examine their activation by their cognate ligands in the 
presence of p 179 or its iodinated analogue in a competitive inhibition assay. Both p 179 
and I -p 179 inhibited 8F9 activation equally well suggesting equivalent binding affinities 
to Ek (Figure 3.3A). Similarly, both analogues strongly inhibited lOCI activation but this 
effect was noticeable at high competitor peptide concentrations (125 JlM) with the I-p179 
showing a slightly higher, although not significantly different (p<0.05), inhibition 
(Figure 3.3B). The inhibitory effect was MHC specific because equimolar concentrations 
of control peptides did not cause any inhibition (Figure 3.3A&B). These results indicate 
that the addition of an iodine atom to the Y192 residue does not significantly alter the 
MHC binding properties ofp179. 
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Figure 3.3 Iodination ofp179 does not influence its MHC binding. A, Activation ofthe 
ELrestricted clone 8F9 by its p2496 ligand (25 nM) in the presence of increasing 
concentrations of the inhibitor peptides p179 and I-p179. IL-2 secretion by the activated 
T cell hybridomas was assessed by CTLL proliferation. p1826 (ALrestricted) was used as 
a negative control. B, Activation of the Ak-restricted clone lOCI to its I-p3041igand 
(0.15 1-1M), in the presence of increasing concentrations of the inhibitor peptides p 179 and 
I-p 179. IL-2 secretion was assessed as above. Ek-restricted p2496 was used as a negative 
control. 
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3.3.4 Generation ofT-cell hybridomas from p179- and I-p179-primed LNCs 
To determine whether iodine modification influences T-cell recognition ofp179 peptide, 
we generated T-cell hybridomas from LNCs separately primed with p179 or I-p179. 
Briefly, CBA/J mice were immunized s. c. with 100 nmol ofp179 or I-p179 in 100 J.ll of 
PBS/CF A emulsion (Mycobacterium butyricum; Difco, Detroit, MI) and nine days later, 
draining LNC were cultured with 20 ).lM ofthe corresponding priming peptide. After 
three days, the stimulated cells were fused with BW5147a-~-lymphoma cells (White et 
al. 1989). The specificity and sensitivity ofthe hybridomas to p179 and I-p179 were 
tested by an activation assay based on IL-2 release. In cultures ofhybridomas derived 
from p179-primed LNC, 128 out of576 wells showed hybridoma growth, and ofthose, 
53 hybridomas were randomly tested. Fifteen hybridomas recognized only p179 and 
seventeen hybridomas cross-reacted with p179 and its iodinated analog. The remaining 
21 hybridomas were non-specific (Table 3.1). In cultures ofhybridomas derived from I-
p 179-primed LNCs, 99 out of 57 6 wells showed hybridomas growth, and of those, 22 
hybridomas were randomly tested. Ten hybridomas recognized only I-p179 and seven 
hybridomas cross-reacted with I-p179 and its non-iodinated analog (Table 3.2). The 
above data demonstrated that I-p179 and p179 elicited cross reactive clones; they also 
elicited monospecific T-cells, which reacted either with I-p179 only, or p179 only. Thus, 
TcR may exist that show a predilection for iodine-modified MHC-peptide complexes, 
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whereas other TcR may not tolerate the presence of iodine within the p179-MHC 
complex. 
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Table 3.1 Screening the specificity ofT-cell hybridomas generated from p179-primed LNC 
Reactivi!): ofh~bridomas generated from 2179-2rimed LNC against 2179 & 1-2179 
h~bridoma p179 (1.25J..1M) 1-p 179 (1.25J..1M) No peptide 
s2ecifici!): name Mean(cpm) • S.O Mean(cpm) • S.O Mean(cpm) • S.O 
p179 HJ5G6 9422 1946 3350 310 2896 976 
HJ5G2 16042 2184 243 33 278 244 
HJ5C1 8929 810 1836 71 506 78 
HJ5E10 9720 386 1981 302 66 1 
HJ5H8 6890 455 69 25 39 11 
HJ3G11 24608 1488 5109 1499 242 75 
HJ1F6 27517 2975 201 17 4607 6183 
HJ4C7 34739 1941 227 49 208 29 
HJ2010 30460 1921 228 14 239 55 
HJ 3012 14560 105 691 34 680 45 
HJ205 26021 3982 290 37 167 35 
HJ1F10 27926 2022 382 95 267 30 
HJ485 26414 88 263 133 152 40 
HJ5H11 38031 5745 392 34 224 59 
HJ1C1 27074 2784 428 131 242 0 
cross-reactive to HJ 5011 14711 508 15181 597 43 22 
p179 & l-p179 HJ4F5 9908 692 11747 805 47 6 
HJ 5A4 10427 1180 12542 129 192 199 
HJ 5A12 11878 412 11207 1024 99 21 
HJ 4A10 5811 751 3454 482 101 37 
HJ 587 10850 1253 12471 926 117 101 
HJ5F2 26143 1896 21839 144 110 6 
HJ 3F12 8548 537 10467 907 309 18 
HJ1G1 23001 2708 27990 1189 176 21 
HJ208 31959 573 29439 998 280 98 
HJ5012 8816 912 10509 798 117 122 
HJ3G5 19443 986 30049 1008 205 66 
HJ1D7 13006 3072 18392 6153 368 54 
HJ 2F11 17826 131 14572 1961 4318 5546 
HJ2H2 16732 545 16081 180 147 40 
HJ 304 14890 626 15802 1953 283 21 
HJ3G1 34560 4804 39003 2230 336 33 
non specific HJ4A1 23024 752 26753 935 12574 12060 
HJ502 18754 12514 26750 4150 24451 2567 
HJ3F9 19281 675 18431 1606 9233 12420 
HJ4C5 32715 1329 36970 1356 29155 5259 
HJ1C4 216 52 2044 291 231 127 
HJ 5A11 10446 831 10923 147 7409 2990 
HJ3H5 23071 156 24424 1245 7860 8248 
HJ202 18798 1720 28018 655 29691 1703 
HJ5B11 18388 103 26210 647 25651 1932 
HJ4E4 667 4 797 25 412 155 
HJ4G6 15583 18 15069 191 18017 129 
HJ 4F12 558 136 238 36 577 285 
HJ 3F6 16195 1122 19291 3465 14230 181 
HJ 3C1 4805 386 2837 259 3800 88 
HJ 3811 16545 4337 17078 1752 233 146 
HJ4G4 123 23 257 14 173 55 
HJ 4H12 17310 1635 7879 687 258 143 
HJ4H6 9292 3174 7397 1049 5284 704 
HJ5E5 1788 220 535 148 194 173 
HJ 5C2 1458 187 188 42 83 19 
HJ5E3 32805 821 29736 637 10788 14489 
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Table 3.2 Screening the specificity ofT-cell hybridomas generated from I-pl79-primed LNC 
Reactivi!Y ofhybridomas generated from 1-~179 ~rimed LNC against ~179 & 1-~179 
hybridomas 1-p179 (5!-lM) p179 (5!-lM) No peptide 
s~ecificity name Mean(cpm) • S.D Mean(cpm) • S.D Mean(cpm) • S.D 
l-p179 HJ 4A11 37892 8597 1151 54 1079 575 
HJ 6812 32539 4072 1483 387 1811 242 
HJ 3F4 17151 965 1115 30 1381 374 
HJ1C7 35808 49 1636 17 460 19 
HJ 108 35591 7529 3485 270 5091 803 
HJ 2012 17310 959 1242 0 565 62 
HJ 2G11 45665 1063 698 106 569 120 
HJ 3G11 42020 54 654 7 599 22 
HJ 4011 16074 780 2804 2140 1220 12 
HJ 5E4 48018 1060 1009 141 897 127 
cross-reactive to HJ4G8 42349 4606 44186 1678 927 237 
p179 & 1-p179 HJ3A6 40810 2739 35502 3118 4857 3831 
HJ 4F12 27480 2749 16300 70 2186 560 
HJ 1A7 50780 977 49302 2470 1004 222 
HJ387 40973 251 40249 3302 752 57 
HJ 5F12 28806 2001 48431 8126 2871 850 
HJ 183 32100 342 37174 70 2343 378 
non specific HJ 2F5 43944 7660 37117 3763 38557 5270 
HJ 6E9 1046 272 744 252 780 90 
HJ 3A12 1938 459 1622 93 1722 180 
HJ 201 1516 208 1876 1136 2117 128 
HJ 3C12 52099 7930 43452 2643 46566 1179 
• The mean (cpm) of values of duplicate wells. 
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3.3.5 Variable effects of iodine on T -cell recognition at the clonal level 
To examine possible effects of the iodinated Y192 on T cell recognition, we generated a 
panel ofT-cell hybridoma clones: 1E7, 2D5 and 2H2 clones were obtained from p179-
primed LNC, whereas 4All and 1B3 clones were generated from I-p179-primed LNC. 
Within the first set, it was found that 1E7 and 2D5 were activated only by pl79 and that 
the incorporation of one iodine atom to Y192 abrogated their receptor engagement 
(Figure 3.4A & B). In contrast, clone 2H2 was activated by both p179 and I-p179 
suggesting that the presence of iodine had a neutral effect on its TCR engagement 
(Figure 3.4C). Within the second set, clone 4All was activated only by the I-pl79 
analogue within the 1-125 nM range, demonstrating that the iodine atom was critical for 
TCR recognition (Figure 3.4D). On the other hand, clone 1B3 showed a preference for 
the iodinated analog but remained reactive to p 179 indicating that the iodine atom was 
not an integral part of its ligand (Figure 3.4E). MAb-mediated blocking assays 
confirmed that all the above clones were Ek -restricted with the exception of 2D5 which is 
A k-restricted (Figure 3.5). Furthermore, RT-PCR analysis showed that 1E7 utilized 
V~lO, 4All utilized V~4, while 2D5, 1B3 and 2H2 utilized V~2 gene families. These 
results confirmed the clonal nature of these hybridomas and further suggested that there 
may be no strict segregation ofV~ family use according to the fine TCR specificity 
(Figure 3.6). 
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Figure 3.4 Variable effects of iodine on T-cell recognition at the clonal level. Hybridoma 
clones 1E7 (A), 2D5 (B) and 2H2 (C) were generated from p179-primed LNCs (1E7 and 
2D5 were obtained from two independent immunizations.) And clones 4All (D) and 1B3 
(E) were generated from I-p179-primed LNCs. LK35.2 cell line was used as APC. Data 
show mean ± SD of cpm values of triplicate wells and are representative of data from 
three independent assays. 
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Figure 3.5 MHC-restriction ofT-cell clones of 1E7 (A), 2D5 (B), 2H2 (C), 4All (D) 
and 1B3 (E). Reactions ofT-cell clones to their ligands were measured in the presence of 
increasing concentration ofblocking Abs, 1-Ek Ab or 1-Ak Ab. A mAb specific for 
influenza nucleoprotein was used as an isotype control. LK35.2 cell line was used as 
APC. Data showed mean ± SD of cpm values of triplicate wells and were representative 
of three experiments. 
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Figure 3.6 V~ family utilization ofT -cell clones. TCR V~ utilization was examined by 
RT-PCR using V~-specific primers (Ju et al. 1995). M: Marker. B: Blank control. G: 
GAPDH. 
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3.3.6 Examination of fine specificity of hybridoma clones by truncation analysis 
To investigate whether the fine specificity of the above clones was linked to recognition 
of distinct determinants within the a.a. 179-194 sequence, we performed truncation 
analysis using the peptide panel shown in Figure 3.7A. The clones 1E7 and 2D5 which 
reacted only against the p179 analog (pep.7) were found to respond to the 11mer Tg 
peptide p184 (pep. 5, aa.184-194) but remained unresponsive to the iodinated analogue I-
p184 (pep.2) (Figure 3.7B & C). In contrast, the clone 2H2 responded to both 11mer 
analogs (pep. 2 and 5) (Figure 3.7D). Conversely, the clone 4A11 recognized only I-
p184 (pep.2) not p184 (pep. 5) (Figure 3.7E), whereas clone 1B3 responded to both p184 
and I-p184 analogs (Figure 3.7F). No clone was activated by either pep.3 or pep.6 
suggesting that R194 is a critical residue. These results established: a) that the R194 
residue is the C-terminal residue ofthe minimal epitope recognized by all clones and b) 
that the x-reactive clones 2H2 and 1B3 recognize an epitope that contains the Y192, i.e. 
they can tolerate the presence of the bulky iodine atom in this position. 
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Figure 3. 7 Truncation analysis of p 179 and I -p 179 by T -cell clones. A, Truncated peptide sequence. Peptide 7 
and 8 containing full sequence as p179 and I-p179, respectively, worked as peptide quality control. Activation 
ofhybrodomas 1E7 (B), 2D5 (C), 2H2 (D), 4A11(E) and 1B3 (F) was measured in the presence of 10 J..LM of 
indicated peptides. LK35.2 cell line was used as APC. 
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Figure 3.8 T-cell clone recognition ofp184 and its iodinated analog. Hybridoma clones 
1E7 (A), 2D5 (B) and 2H2 (C) were generated from p179-primed LNCs and clones 4All 
(D) and 1B3 (E) were generated from I-p179-primed LNCs. LK35.2 cell line was used as 
APC. Data show mean± SD of cpm values of triplicate wells and are representative of 
data obtained in three assays. 
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3.4 Discussion 
Tg is the only self antigen that stores iodide and organifies it in the form of iodotyrosyl or 
iodothyronine residues. This post-translational modification varies according to the 
environmental supply of iodine and has immunological consequences due to formation of 
neoantigenic determinants. For example, thyroid-infiltrating T cells are elicited by Tg 
peptides containing hormonogenic sites (Champion et al. 1991, Kong et al. 1995) or 
iodotyrosyls (Li and Carayanniotis 2006). Iodine can also have variable influences on 
peptides of known immunogenicity as it can increase, decrease or not alter their antigenic 
and immunogenic potency (Li and Carayanniotis 2006). In this context, we have 
described in a parallel study that iodine enhances the immunogenicity of the p179 peptide 
with no apparent effects on its pathogenicity (Li et al. submitted for publication). These 
observations and the prior finding that processing ofhTg in HLA-DR3 transgenic mice 
generates the overlapping peptide (181-195) (Flynn et al. 2004) prompted us to examine 
how iodine influences recognition of p 179 at the clonal T cell level. 
Our results demonstrate that processing of mTg in vivo or in vitro seems to weakly prime 
p179-specific T cells, confirming its subdominant nature. However, mTg-primed LNC do 
not react against I-p179 suggesting that mTg does not harbour the iodinated analog under 
steady-state conditions. So far, subdominant Tg T-cell epitopes have been localized 
within seven Tg peptides: (179-194), (418-432), (1518-1532), (2079-2093), (2340-2359) 
(2549-2560) and (2695-2713) (Flynn et al. 2004, Carayanniotis et al. 1994, Karras et al. 
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2005, Hutchings et al. 1992). Identification of a dominant Tg epitope which can activate 
mTg-primed LNC at concentrations equimo1ar to those of intact Tg remains problematic, 
and it is uncertain to what extent a 330 kDa Tg monomer can be quantitatively processed 
in vitro to yield any given peptide with an approximately 150-fold smaller molecular 
mass (Hutchings et al. 1992, Carayanniotis et al. 1994). 
The I-p179 analog binds to Ak or Ek molecules almost as well as p179, yet the presence 
of one iodine atom at Y192 can exert extremely variable influences at the clonal T cell 
level. Clones 1 E7 and 2D5 must represent subsets ofT cells whose fine specificity is 
negatively impacted by iodine, presumably through a steric hindrance effect. Conversely, 
the absence of iodine completely abrogates the reactivity of clone 4A 11 which likely 
represents T cell subsets monospecific for the neoantigenic determinant. These cells will 
be elicited following animal challenge with I-p179, and they may even occur at a 
frequency higher than p 179-specific T cells to account for the higher immunogenicity of 
I-p179. However, they are not expected to contribute to EAT ifl-p179 is not 
constitutively expressed in normal Tg. Their putative effector function would be 
demonstrable only when increased ingestion of iodine might promote iodination ofthe 
Y192 residue. Lastly, the cross-reactive receptors on clones 2H2 and 1B3 may be 
expressed on effector T cells in EAT elicited by either analog, and may account, to a 
large extent, for the mild thyroiditogenicity ofp-179 and I-p179. 
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The truncation analysis data mapped the minimal epitope recognized by all clones within 
the 11mer p184 (184-194) peptide. The R194 residue comprises the C-terminal aa residue 
of this epitope because its removal abrogates the reactivity of all clones. Although the N-
terminal end of the minimal epitope has not been formally assigned, this sequence differs 
only at two aa positions (!185- V185 and N191- 8191) from the homologous 
thyroiditogenic sequence in human Tg (Flynn et al. 2004). The data also demonstrate that 
the cross-reactivity of clones 2H2 and 1B3 cannot be explained by recognition of an 
identical minimal epitope lacking Y192. Instead, these findings argue for the presence, 
within the normal receptor repertoire, ofTcR capable of tolerating the bulky iodine atom 
regardless of whether the initiating stimulus is p 179 or I -p 179. 
In conclusion, the current data support the view that iodination ofTg may have 
pleiotropic effects on Tg-reactive T cell clones. Any given iodinated neoantigenic 
determinant may turn on some autoreactive T cells but simultaneously suppress others 
specific for the non iodinated analog. Thyroiditogenicity may be determined by the 
combined net effect of this modification at the polyclonallevel. Overall, highly iodinated 
Tg may become more immunopathogenic than normal Tg because of: a) creation of 
iodinated neoantigenic peptides which preferentially activate thyroiditogenic T cells; and 
b) generation of non iodinated but cryptic pathogenic peptides generated by altered 
processing ofTg in APC (Dai et al. 2002). The potential role of each category of 
determinant in the development of clinical disease remains to be elucidated. 
61 
3.5 Future directions 
Since p179 is generated following processing of intact Tg, it is plausible that I-p179 may 
be generated under conditions favoring iodotyrosyl formation at Y192. Future studies can 
examine whether I-p179 can be generated by processing of highly iodinated Tg (1-Tg), 
since normal Tg-primed LNC did not respond to I-p179, suggesting that I-p179 cannot be 
generated naturally following processing of normal Tg (unpublished data). To answer this 
question, CBA/J mice will be immunized with I-T g and, then, the I -p 179-specific 
proliferative response of I-Tg-primed LNC will be tested. If a significant proliferative 
response to I-p179 is detected, it will indicate that I-p179 can be generated by processing 
ofTg with increased iodine content. In a parallel study, we will examine whether the 
neoantigenic determinant generated by iodination of p 179 is expressed in the thyroid. 
CBA/J mice will be given excess dietary iodine, such as 0.05% Nal-containing water to 
enhance the iodine incorporation ofTg in thyroid for several weeks. Then, primary 
thyrocytes will be collected from these mice treated with excess iodine and cultured with 
INF-y to up-regulate MHC-11 molecules (Kimura et al. 2005). These IFN-y-treated 
thyrocytes will be used as APC with pathogenic Tg determinants presented on their 
surface for activation assay ofl-p179-specific T-cell clone 4All. If a significant response 
is detected, it will indicate that the iodotyrosyl determinant within I-p179 is formed in the 
thyroid and it recruits a new subset ofT -cells which home to the thyroid and are involved 
in the pathological damage. 
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The hybridoma clones generated in this study will provide very useful tools to address the 
following questions: First, p179 is pathogenic in CBA/J mice, as shown in previous 
studies (unpublished data), suggesting that p179 can be presented on thyroid. The present 
data show that there are two subsets ofT-cells activated following p179 immunization. It 
is not clear which subset ofT -cells leads to the thyroid lesion. We can use clones 
1E7/2D5 and 1B3, representing these two subsets ofT-cells, to examine which subset can 
be activated by thyrocytes which process and present Tg in thyroid. In the activation 
assay, primary thyrocytes from CBA/J mice can be used as APC. Second, we had 
observed that pl79 contained subdominant epitope(s) since Tg-primed LNCs reacted to 
free peptide 179 at high concentrations. This might be due to the generation of p 179 by 
processing of intact Tg in vivo being not efficient enough to stimulate a large number of 
peptide-specific T-cells. The subdominance ofp179 in intact Tg can be tested by using 
p179-specific T-cell clones (1E7 & 2D5). Third, the parameters that influence the 
processing ofTg remain an open question. The pleiotropic cytokine interleukin (IL)-6 has 
been shown to alter antigen processing and presentation in dendritic cells (DCs) by 
changing the pH of peripheral, early endosomal compartments (Drakesmith et al. 1998). 
We can use these T -cell clones to further examine whether treatment of DCs with IL-6 
could alter the hierarchy of the subdominant determinant( s) within p 179 following 
processing of intact Tg. 
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CHAPTER4 
SEARCHING FOR DOMINANT A k-BINDING PEPTIDES IN MOUSE TG 
4.1 Abstract 
So far, no dominant peptide has been identified in Tg due to its large size ( dimeric MW 
660 kD). Studies about antigen processing have shown that the dominant determinant(s) 
might be presented adjacent to endopeptidase cleavage sites. In this study, we searched 
Ak-binding motifs close to cleavage sites in mouse Tg (mTg) sequence by computerized 
algorithms to predict potential dominant determinants. According to the identified 
cleavage sites in human Tg (hTg), we have identified 11 corresponding cleavage sites in 
mTg, four cleavage sites for cathepsin L (P' 1 2388, P' 1 2451, P' 1 2490 and P' 1 2657), 
three cleavage sites for cathepsin B (P' 1 531, P' 1 795 and P' 1 2486) and four cleavage 
sites for cathepsin D (P' 1 550, P' 1 1833, P' 1 2467 and P' 1 2642). Subsequently, 20 amino 
acid sequences adjacent to these endopeptidase cleavage sites were scanned for A k_ 
binding motifs. A total of eight dominant Tg peptide candidates were unveiled in this 
study. Since these Tg peptides are the closest to cleavage sites in Tg sequence, they might 
have priority to bind to the A k molecule, and be presented them on the surface of APCs to 
auto-reactive T-cells to elicit a dominant response to Tg. The potential dominance of 
above Tg peptides should be empirically examined in a future study. 
64 
4.2 Introduction 
Twenty-three pathogenic Tg peptides have so far, been identified in Tg (Carayanniotis 
2003, Flynn et al. 2004, Li and Carayanniotis 2006), but none of them comprises an 
immunodominant determinant (Carayanniotis and Rao 1997, Carayanniotis and Kong 
2000). The observations that EAT is under control of the I-Ak subregion (Vladutiu and 
Zaleski 1981, Beisel et al. 1982) and administration ofanti-Ak Abs protects mice from 
EAT induction (Vladutiu and Steinman 1987) strongly suggest that Tg carries dominant 
A k -binding determinant(s ). Following these clues, Verginis et al. searched for the 
complete mTg sequence to detect dominant pathogenic T-cell epitopes containing Ak-
binding motifs (Verginis et al. 2002). Due to the large size ofTg, a total of 104 Ak-
binding sites were found. Therefore, it became apparent that it is unlikely to identify 
dominant epitope( s) simply depending on this approach. 
Antigen processing studies have indicated that determinants close to endopeptidase 
cleavage sites become more easily available to bind to MHC molecules (Sercarz et al. 
1993, Schneider et al. 2000). This renders it likely that dominant determinant(s) are 
localized adjacent to endopeptidase cleavage points. Data analysis following proteolysis 
of rabbit Tg by human cathepsins L, B and D allowed Dunn et al. to identify the 
cathepsin cleavage points in the human Tg sequence (Dunn et al. 1991). Based on the 
above observations, we proceeded to identify the cathepsin cleavage points in mTg and 
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search for putative dominant A k -binding peptide( s) localized close to these cleavage 
points. 
4.3 Results 
4.3.1 Algorithm based putative dominant Ak-binding peptides in mTg 
Extrapolating from the known cathepsin cleavage sites in the hTg sequence (Dunn et al. 
1991), we identified homologous sites within mTg sequence (Table 4.1). The four 
cathepsin L cleavage sites showed P' 1 residue at a.a. positions 2388, 2451, 2490 and 2657; 
the three cathepsin B cleavage sites showed P' 1 residue at a. a. positions 531, 795 and 
2486; the four cathepsin D cleavage sites showed P'1 residue at a.a. position 550, 1833, 
2467 and 2642 (Table 4.1). We next searched for Ak-binding motifs (Altuvia et al. 1994) 
within 20 a.a. residue segments adjacent to the above endopeptidase cleavage sites. Eight 
peptides met this rule in the mTg sequence (Table 4.2). We arbitrarily defined the 
boundaries ofthese peptides by adding five a.a. residues at theN- and C-termini of the 
identified Ak-binding motifs. The final eight sequences varied from13-17 a.a., which is a 
favorite length for MHC class 11-binding peptides. Three of eight Tg peptides (p2369, 
p2438 and p2490) were located closely to cathepsin L cleavage points (P' 1 2388, P' 1 2451 
and P' 1 2490); four (p557, p1822, p1838 and p2467) were found adjacent to cathepsin D 
cleavage points (P' 1 550, P' 1 1833 and P'1 2467), and two ofthem, p1822 and p1838 were 
at both sides of cleavage site P' 1 1833. Only one peptide (p771) was found close to the 
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cathepsin B cleavage site P' 1 795. Coincidentally, one of the above Tg peptides, p2369 
also has three Ek-binding motifs (Altuvia et al. 1994), indicating that this peptide could be 
presented in the context ofboth Ak and Ek molecules. 
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Table 4.1 The possible cleavage sites in mTg by cathepsin L, Band D 
Endopeptidase 
Cathepsin L 
CathepsinB 
Cathepsin D 
QLFR 
KLLA 
LIGG 
FSRK 
RVVG 
REVA 
KVDL 
FLVS 
ATEL 
DGQY 
FSNF 
PI P' b 1- n+ I sequence 
KALLMGGSALS 
VSGPFHYWGPVVDGQ 
SQDDGLINRA 
AAEFATPWP 
NEGFKVNLQENQDAL 
£RNESLFLQ 
LIGGSQDDGLINRA 
SLLELPEFL VFLQR 
FSPVDITOVI 
LREL£SRRLKRPL 
IRSGNPNYPHEFS 
P'! residue 
2388 
2451 
2490 
2657 
531 
795 
2486 
550 
1833 
2467 
2642 
ap sequences are based on the eDNA-derived sequence ofmTg (Kim et al. 1998). 
b Homologous rabbit Tg residues identified by Dunn et al. (Dunn et al. 1991) are 
underlined. 
c P' residue no. is based on the eDNA-derived sequence ofmTg (Kim et al. 1998). 
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Figure 4.1 Cathepsin cleavage sites within mTg sequence are indicated by arrows. 
Numbers inducate the a.a. coordinates ofTg peptides with known pathogenicity and/or T-
cell reactivity. 
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Table 4.2 Putative Ak-binding peptides adjacent to possible cleavage sites within mTg 
Amino acid Cleavage Peptide 
coordinates a Motif-containing seguenceb site P' denotation 
557-573 FL VFLQRA VSVPEDIAR 550 p557 
771-787 QNGDGOELTPAALLMKI 795 p771 
1822-1832 SDFPGDMATEL 1833 p1822 
1838-1850 ITQVIIYffi]SHSLP 1833 p1838 
2369-2387 DV ASIHLLISR!PTR!LQLFRc 2388 p2369 
2438-2450 ANILNDAQTKLLA 2451 p2438 
2467-2478 LREL S KRP 2467 p2467 
2490-2504 SQDDGL N KAVKQ 2490 p2490 
a Amino acid coordinates are based on eDNA-derived sequence ofmTg (Kim et al. 1998). 
b The underlined sequences represent motif A: [DEHNQ]-{NQ}-X- [ILTV]-X-{FHWY}-
[ACFILMPTVWY]; the bold sequences represent motifB: [CDEHNQY]-{DE}-X-
[ILTV]-[DEHQN]; the squared sequences represent motifC: [CILNPTV]-[CHNSTY]-
[CKNRST]; [] represents inclusion and {} represents exclusion of indicated amino acids 
at this position, X denotes any amino acid at this position (Altuvia et al. 1994) 
c This peptide also contains an Ek-binding motif A: [ACFILMPTVWY]-X-
[ ACFILMPTVWY]-{DE}-{DE}-{HKR}-{FHWY}-[KR] (Altuvia et al. 1994) (shown 
in p2369 as ASIHLLISR); two Ek-binding motifs C: [AILSTV]-{NQ}-
[ACFILMPTVWY]-{DE}-[ACFILMPTVWY]-{NQ}-[DEKNQR] (Altuvia et al. 1994) 
(shown in p2369 as IHLLISR and TRLQLFR). 
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Figure 4.2 Mapping putative dominant mTg peptides with Ak·binding motifs adjacent to 
cathepsin cleavage sites. Numbers indicate the a. a. coordinates of these peptides. 
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4.4 Discussion 
Despite the fact that 23 pathogenic epitopes have so far been mapped in Tg, none of them 
meets the conventional criteria for immunodominance, i.e. is not recognized by Tg-
primed LNC in vitro and conversely do not prime LNC so that they can be stimulated 
equally well by equimolar amounts of free peptide or intact Tg in vitro. There has been 
some skepticism as to whether the large Tg molecule can be efficiently processed in vitro 
within the 1-10 fJM ( 330-3300 f..tg/ml) concentration range to yield any given peptide 
(Carayanniotis 2003, Flynn et al. 2004, Li and Carayanniotis 2006, Carayanniotis and 
Rao 1997, Carayanniotis and Kong 2000). However, dominant epitopes could still exist 
but remain undiscovered because of the large size ofTg and the application of the 
particular methodologies used. 
In this study, we explored, on a theoretical basis, the number as well as the localization of 
putative dominant Tg epitopes based on a rationale different from those applied before in 
the field. We took into account the results of an earlier study which identified cleavage 
sites of rabbit Tg by human cathepsins B, D, L (Dunn et al. 1991 ). The P' 1-P' n+I a.a. were 
sequenced in proteolytic fragments and the homologous points were localized in hTg 
since the primary sequence of rabbit Tg is not available. We then extrapolated these sites 
into the known homologous sequence ofmTg. We further took into account a view, 
expounded mainly by E. Sercarz, that immunodominant peptides are usually localized 
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close to endopeptidase cleavage sites (Sercarz et al. 1993, Sercarz 2002). According to 
this view, crypticity may result from either excessive or limited proteolysis of an antigen, 
facilitating the destruction or the poor generation of a given determinant, respectively. 
This concept was supported by studies with the myelin basic protein (MBP) peptide (89-
101) (Anderton et al. 2002, Manoury et al. 2002). There are three overlapping 
determinants in this peptide, (89-94), (92-98), and (95-101), butT-cell responses were 
detected only against the two flanking determinants, when intact MBP was used as an 
immunogen (Anderton et al. 2002). It was subsequently found that there is an asparagine 
endopeptidese (AEP) cleavage site at Asn94 which probably ruins MBP (92-98) during 
processing, leading to the crypticity of this peptide (Manoury et al. 2002). 
This concept is also eloquently supported by the map of the 23 known pathogenic 
peptides in Tg. Twenty one of these determinants are found far from endopeptidase 
cleavage points (Figure 4.1). Enzymatic processing ofTg may not adequately expose 
these peptides, rendering them as cryptic. On the other hand, the Ak-restricted mTg 
peptide (1826-1835) (Verginis et al. 2002), which has been shown to be thyroiditogenic 
in CBA/J mice, contains a cathepsin D cleavage site (P'1833) and therefore, p1826 may 
be destroyed during Tg processing of intact Tg by cathepsin D. An interesting case can be 
made for the pathogenic but cryptic Tg peptide (2495-2503), presented in the context of 
Ek and As (Rao et al. 1994), which maps closely to the cathepsin L cleavage site (P'2490). 
According to the view presented above this peptide should have been likely to behave as 
dominant. However, we have found an Ak-binding motif( a.a. 2493-2497) right after the 
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P' 1 2490 cleavage point, overlapping two a.a. with p2495. Thus, there may be an 
additional Ak-restricted epitope at this site which, as the first available epitope, may have 
priority over p2495 to bind to MHC, rendering p2495 as cryptic. 
Among the eight new putative Ak-binding peptides (Figure 4.2) adjacent to possible 
endopeptidase cleavage sites, two, p1822 (a.a. 1822-1832) and p2490 (a.a. 2490-2504) 
overlap with the previously identified pathogenic peptides p1826 and p2495 (Verginis et 
al. 2002, Rao et al. 1994 ). p 1826 contains a cathepsin D cleavage point (P' 1833) and 
p2490, although identified earlier as a putative Ak-binder (Verginis et al. 2002), it was 
never synthesized and tested because of its overlap with p2495. TheN-terminus ofp557 
and p1838 was 2:6 a.a. away from the cathepsin cleavage sites and the C-terminus of 
p771 was 9 a.a. away from the cathepsin B cleavage site (P' 1 795) (Figure 4.2). These 
peptides, if generated, may require further a.a trimming by exopeptidase before or after 
MHC binding in order to form T-cell activating determinants. 
The analysis described herein has several caveats that need to be addressed. First, it is not 
known whether mouse cathepsins can cleave mTg at the indicated sites extrapolated from 
the hTg sequence. Second, enzymatic activity may be influenced by cytokines resulting 
in alternate modes of processing within APC. For example, IL-6 has been shown to alter 
the hierarchy ofT -cell determinants by influencing the pH of early endosomes in DCs 
(Drakesmith et al. 1998). Third, and most importantly, the source of APC may play a 
pivotal role in what enzymes participate for the generation of the given determinants. It 
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should be emphasized that, despite their crypticity, all known Tg epitopes are pathogenic, 
i.e. they must be generated intrathyroidally and presented in the context of MHC class II 
molecules to be seen as targets of adoptively transferred CD4+ effector T cells. Currently, 
it is not clear what cells carry out this APC function in the thyroid, but they must 
comprise either DC or thyrocytes with upregulated class II MHC expression (Kimura et 
al. 2005). The present theoretical study aims to identify peptides with immunodominant 
characteristics in APC of peripheral lymphoid tissues, as outlined by Sercarz (Sercarz et 
al. 1993, Sercarz 2002). 
4.5 Future Directions 
We have identified 8 peptide sequences that express the combined features ofbeing 
mapped close to cathepsin cleavage sites and carrying Ak-binding motifs. The working 
hypothesis is that at least some of them may contain immunodominant Tg determinants. 
These peptides can be synthesized at high purity (>90% ), emulsified in CF A and 
delivered into several strains of mice of the H-2k haplotype. The capacity of these 
peptides to elicit T-cell and/or B-cell responses, as well as EAT will then be examined. 
Most importantly, peptide-primed LNC from draining lymph nodes can be assayed for 
their reactivity to intact Tg in vitro; and conversely, Tg-primed LNC can be tested for 
their proliferation to each peptide. Positive response in both of these tests will support the 
discovery of immunodominant determinant( s ). 
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